KemPharm to be Added to the Nasdaq Biotechnology Index Effective December 20, 2021

Rhea-AI Summary

KemPharm (NASDAQ: KMPH) announced its inclusion in the Nasdaq Biotechnology Index, effective December 20, 2021. This milestone enhances the company's profile among biotechnology investors.

Travis C. Mickle, CEO, stated that this addition follows their recent uplisting to the Nasdaq Global Select Market and is part of a transformative year for KemPharm. The Nasdaq Biotechnology Index tracks the performance of biotechnology and pharmaceutical securities and selects its constituents annually based on specific eligibility requirements.

Positive

• Inclusion in the Nasdaq Biotechnology Index enhances visibility and credibility among investors.
• Follows recent uplisting to the Nasdaq Global Select Market, indicating progress.

Negative

• None.

CELEBRATION, Fla., Dec. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced its common stock has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) in accordance with an annual reconstitution of the index. KemPharm’s inclusion in the Nasdaq Biotechnology Index will become effective prior to market open on Monday, December 20, 2021.

“We are pleased that KemPharm has been added to the Nasdaq Biotechnology Index, which further raises our profile in the investment community given the importance of the index to funds and portfolio managers focused on the biotechnology sector,” said Travis C. Mickle, Ph.D., President and Chief Executive Officer of KemPharm. “Our inclusion in the Nasdaq Biotechnology Index follows the recent uplisting of our stock to The Nasdaq Global Select Market in October and continues what has been a transformative year for our listing and our company as a whole.”

The Nasdaq Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market^® (Nasdaq^®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The Nasdaq Biotechnology Index is calculated under a modified capitalization-weighted methodology. Companies in the Nasdaq Biotechnology Index must meet eligibility requirements, including minimum market capitalization, average daily trading volume and seasoning as a public company, among other criteria. Nasdaq selects constituents once annually in December.

For more information about the Nasdaq Biotechnology Index, please visit https://indexes.nasdaqomx.com/Index/Overview/NBI.

About KemPharm:

KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT^® (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT^® technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm’s prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH). In addition, the U.S. Food and Drug Administration (FDA) has approved AZSTARYS^®, a once-daily treatment for ADHD in patents age six years and older containing KemPharm’s prodrug, serdexmethylphenidate (SDX), and APADAZ^®, an immediate-release combination product containing benzhydrocodone, KemPharm’s prodrug of hydrocodone, and acetaminophen. For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter, LinkedIn, Facebook and YouTube.

Caution Concerning Forward Looking Statements:

This press release may contain forward-looking statements made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to KemPharm and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning KemPharm’s business are described in detail in KemPharm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, and KemPharm’s other filings with the Securities and Exchange Commission. KemPharm is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

KemPharm Contacts:

Tiberend Strategic Advisors, Inc.
Jason Rando/Maureen McEnroe, CFA
(212) 375-2665 / 2664
jrando@tiberend.com
mmcenroe@tiberend.com

FAQ

When will KemPharm be included in the Nasdaq Biotechnology Index?

KemPharm will be included in the Nasdaq Biotechnology Index effective December 20, 2021.

What is the significance of KemPharm's inclusion in the Nasdaq Biotechnology Index?

Inclusion raises KemPharm's profile in the investment community, appealing to funds and portfolio managers focused on biotechnology.

What recent milestones has KemPharm achieved?

KemPharm recently uplisted to the Nasdaq Global Select Market and has now been added to the Nasdaq Biotechnology Index.

What criteria does a company need to meet to be included in the Nasdaq Biotechnology Index?

Companies must fulfill requirements like minimum market capitalization, average daily trading volume, and seasoning as a public company.